Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sawai Soars To New Heights In US But Flounders In Domestic Market

One-Off Expenses, NHI Revision And Shipment Limitations All Hurt Japanese Firm

Executive Summary

While Sawai’s dominant Japanese business appeared under some strain as the firm started its 2022 financial year, the company appears confident that it is still on track to meet its annual forecast.

You may also be interested in...



Upsher-Smith Shuffles Portfolio With A Pair Of Deals

Sawai’s Upsher-Smith business in the US has announced a pair of deals that will see the firm expand an existing partnership with Appco for a “near-term generic product opportunity” as well as divesting two “dormant” ANDAs in favor of a focus on more immediate assets.

Dr Reddy’s Settles US Patent Litigation With Intercept On Ocaliva

Dr Reddy’s is the first of six generics firms to challenge Intercept’s Ocaliva patents to reach a settlement, and will be able to market its product in the US from 2035 onward.

Sawai To Take Over Facilities Owned By Scandal-Hit Kobayashi Kako

Kobayashi Kako has agreed to transfer ownership of eight of its production, research and distribution facilities to Sawai, which will use them to expand the manufacturing of its own generics. Business was suspended at Kobayashi Kako for 116 days this year after the company’s manufacturing deficiencies were linked to two deaths.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB152109

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel